معرفی
Brian K. Law, Ph.D., is an Associate Professor and Vice Chair for Faculty Affairs in the Department of MD-PHARMACOLOGY / THERAPEUTICS at the University of Florida. His research focuses on cancer biology, particularly the role of cyclin-dependent kinases (Cdks), protein disulfide isomerases (PDIs), and death receptor signaling in tumor progression and therapeutic resistance. His work integrates drug discovery, cellular signaling, and molecular mechanisms to develop novel anticancer strategies.
Dr. Law teaches advanced pharmacology and therapeutics courses, emphasizing critical thinking through literature analysis and experimental design. He has pioneered studies on Disulfide Bond Disrupting Agents (DDAs) and their role in activating death receptors (DR4/5) to induce apoptosis in cancer cells. His lab also investigates CDCP1-mediated breast cancer metastasis and the interplay between the mTOR and TGFβ pathways in mammary tumorigenesis.
His grants include funding from the National Cancer Institute (NCI), Florida Biomedical Research Program, and industry partners like Tranexamic Technologies. Key projects include developing synthetic-lethal strategies for EGFR+/HER2+ cancers and repurposing tranexamic acid for anticancer therapy.
Dr. Law's lab is a hub for translational research, bridging basic science and clinical applications. His contributions span over 100 peer-reviewed articles and patents on small-molecule inhibitors, protein folding therapeutics, and drug-resistant cancer models.
